{
  "docId": "019de072-0f48-75dc-8e26-6c36719c246a",
  "docSlug": "59aa3600901f9a5fdbc1ca4ce261b5cc",
  "documentTitle": "Vigil Neuroscience | IPO Presentation Deck | 54 slides",
  "authorId": "vigil-neuroscience",
  "authorName": "Vigil Neuroscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 41,
  "pageCount": 54,
  "prevPage": 40,
  "nextPage": 42,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses checkmarks for completed milestones and empty squares for future milestones, effectively acting as a status tracker.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-0f48-75dc-8e26-6c36719c246a/41",
  "deckHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a",
  "deckJsonHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a.json",
  "deckAnchorHref": "/decks/019de072-0f48-75dc-8e26-6c36719c246a#slide-41",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.65,
        "x": 0.03,
        "y": 0.62
      },
      "kind": "list",
      "text": "Select lead development candidate - Q1'2022\nManufacturing scale-up\nConduct IND-enabling toxicology studies\nInitiate a first-in-human healthy volunteer study for lead development candidate",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "62905a33-566a-43de-9a0f-91614abdda02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "list",
      "text": "Identified and optimized lead candidate series of compounds\nIdentified novel second series of compounds\nPreclinical studies with lead series of compounds demonstrated:\n- Potency and selectivity\n- CNS penetration\n- TREM2 target engagement\n- Initial tolerability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9a586e5-c6ae-443e-88fd-92b2ef76729e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Small Molecule TREM2 Agonist Program Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "751b9dc7-d098-465a-b3d0-60171938f774",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "764805a4-517b-42a3-b33b-55cb4b4bbd35",
      "evidence": "The slide lists past achievements and future milestones in a sequential manner.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}